Xtl Biopharmaceuticals (XTLB) Depreciation & Amortization (CF) (2009 - 2016)
Xtl Biopharmaceuticals (XTLB) posted quarterly Depreciation & Amortization (CF) of $1000.0 for Q2 2016, down 50.0% year-on-year from $2000.0 in Q3 2015, and down 50.0% on a QoQ basis from $2000.0 in Q4 2015.
Xtl Biopharmaceuticals (XTLB) Depreciation & Amortization (CF) (2009 - 2016) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $1000.0 the latest figure, recorded in Q2 2016.
- Quarterly Depreciation & Amortization (CF) fell 50.0% year-over-year to $1000.0 in Q2 2016, while the trailing twelve-month figure through Mar 2017 was $1000.0 (down 80.0% YoY) and the FY2024 annual result came in at $199000.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) fell to $1000.0 in Q2 2016 per XTLB's latest filing, from $2000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for XTLB reached as high as $79000.0 in Q2 2013 and fell as low as $1000.0 in Q3 2015.
- A 4-year average of $30916.7 and a median of $11000.0 in 2014 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2015 — Depreciation & Amortization (CF) tumbled 90.91% — and 2016, when it plunged 50.0%.
- Year by year, Depreciation & Amortization (CF) stood at $79000.0 in 2013, then slumped by 87.34% to $10000.0 in 2014, then plunged by 80.0% to $2000.0 in 2015, then tumbled by 50.0% to $1000.0 in 2016.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1000.0, $2000.0, and $1000.0 for Q2 2016, Q4 2015, and Q3 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 1,000.00 |
| Jun 30, 2016 | 1,000.00 |
| Dec 31, 2015 | 2,000.00 |
| Dec 31, 2015 | 2,000.00 |
| Sep 30, 2015 | 1,000.00 |
| Sep 30, 2015 | 1,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Dec 31, 2014 | 10,000.00 |
| Dec 31, 2014 | 10,000.00 |
| Sep 30, 2014 | 11,000.00 |
| Sep 30, 2014 | 11,000.00 |
| Jun 30, 2014 | 11,000.00 |
| Jun 30, 2014 | 11,000.00 |
| Mar 31, 2014 | 20,000.00 |
| Mar 31, 2014 | 20,000.00 |
| Dec 31, 2013 | 79,000.00 |
| Dec 31, 2013 | 79,000.00 |
| Sep 30, 2013 | 77,000.00 |
| Sep 30, 2013 | 77,000.00 |